EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PEGylated liposomes for diagnosis of polyethylene glycol allergy

Griffith B Perkins, Matthew J Tunbridge, Plinio R Hurtado, James Zuiani, Shweta Mhatre, Kwok Ho Yip, Thanh-Thao Adriana Le, Carlo Yuson, Frank Kette, Pravin Hissaria

Journal of Allergy and Clinical Immunology · 2024-08 · 154 (2) · 503-507.e1

DOI: 10.1016/j.jaci.2024.03.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024-08. Verfasst von Griffith B Perkins und 9 weiteren Autor:innen. Beteiligte Einrichtung: Adelaide Medical School, University of Adelaide, Adelaide, Australia; Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide…. Hauptthemen laut MEDLINE: Polyethylene Glycols, Liposomes, Skin Tests, Drug Hypersensitivity. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Adelaide Hospital Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Polyethylene glycol (PEG) is a nonprotein polymer that is present in its native (unbound) form as an excipient in a range of products. It is increasingly being utilized clinically in the form of PEGylated liposomal medications and vaccines. PEG is the cause of anaphylaxis in a small percentage of drug reactions; however, diagnosis of PEG allergy is complicated by the variable and poor diagnostic performance of current skin testing protocols. OBJECTIVE: We assessed the diagnostic performance of PEGylated lipid medications as an alternative to currently described tests that use medications containing PEG excipients. METHODS: Nine patients with a strong history of PEG allergy were evaluated by skin testing with a panel of PEG-containing medications and with a PEGylated lipid nanoparticle vaccine (BNT162b2). Reactivity of basophils to unbound and liposomal PEG was assessed ex vivo, and specificity of basophil responses to PEGylated liposomes was investigated with a competitive inhibition assay. More detailed information is provided in this article's Methods section in the Online Repository available at www.jacionline.org. RESULTS: Despite compelling histories of anaphylaxis to PEG-containing medications, only 2 (22%) of 9 patients were skin test positive for purified PEG or their index reaction-indicated PEG-containing compound. Conversely, all 9 patients were skin test positive or basophil activation test positive to PEGylated liposomal BNT162b2 vaccine. Concordantly, PEGylated liposomal drugs (BNT162b2 vaccine and PEGylated liposomal doxorubicin), but not purified PEG2000, consistently induced basophil activation ex vivo in patients with PEG allergy but not in nonallergic controls. Basophil reactivity to PEGylated nanoparticles competitively inhibited by preincubation of basophils with native PEG2000. CONCLUSION: Presentation of PEG on the surface of a lipid nanoparticle increases its in vivo and ex vivo allergenicity, and improves diagnosis of PEG allergy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsLiposomesSkin TestsDrug HypersensitivityBasophilsHumansFemaleMaleMiddle AgedAdultAgedAnaphylaxisNanoparticles

Stichwörter der Autor:innen

BNT162b2COVID-19PEG allergyallergy diagnosisbasophil activationlipid nanoparticleliposomemRNA vaccinepolyethylene glycolvaccination

Substanzen

Polyethylene GlycolsLiposomes

Autor:innen und Institutionen

  • Adelaide Medical School, University of Adelaide, Adelaide, Australia; Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; Immunology Directorate, SA Pathology,…
  • Adelaide Medical School, University of Adelaide, Adelaide, Australia; Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, Australia; Immunology Directorate, SA Pathology, Adelaide, Australia.
  • Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
  • Department of Allergy and Immunology, Royal Adelaide Hospital, Adelaide, Australia.

Förderung

  • Royal Adelaide Hospital Research Fund

Zitieren

APA

Perkins, G. B., Tunbridge, M. J., Hurtado, P. R., Zuiani, J., Mhatre, S., Yip, K. H., Le, T. A., Yuson, C., Kette, F., & Hissaria, P. (2024). PEGylated liposomes for diagnosis of polyethylene glycol allergy. Journal of Allergy and Clinical Immunology, 154(2), 503-507.e1. https://doi.org/10.1016/j.jaci.2024.03.030

Vancouver

Perkins GB, Tunbridge MJ, Hurtado PR, Zuiani J, Mhatre S, Yip KH, et al. PEGylated liposomes for diagnosis of polyethylene glycol allergy. Journal of Allergy and Clinical Immunology. 2024;154(2):503-507.e1. doi:10.1016/j.jaci.2024.03.030

BibTeX
@article{Perkins2024,
  author = {Perkins, Griffith B and Tunbridge, Matthew J and Hurtado, Plinio R and Zuiani, James and Mhatre, Shweta and Yip, Kwok Ho and Le, Thanh-Thao Adriana and Yuson, Carlo and Kette, Frank and Hissaria, Pravin},
  title = {PEGylated liposomes for diagnosis of polyethylene glycol allergy},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2024},
  volume = {154},
  number = {2},
  pages = {503--507.e1},
  doi = {10.1016/j.jaci.2024.03.030}
}
Kostenlos starten →